Search results
Results from the WOW.Com Content Network
Gram-negative bacteremia occurs more frequently in elderly populations (65 years or older) and is associated with higher morbidity and mortality in this population. [23] E.coli is the most common cause of community-acquired bacteremia accounting for approximately 75% of cases. [24] E.coli bacteremia is usually the result of a urinary tract ...
E. coli bacteria often carry multiple drug resistance plasmids, and under stress, readily transfer those plasmids to other species. Mixing of species in the intestines allows E. coli to accept and transfer plasmids from and to other bacteria. Thus, E. coli and the other enterobacteria are important reservoirs of transferable antibiotic ...
Enterotoxigenic Escherichia coli (ETEC) is a type of Escherichia coli and one of the leading bacterial causes of diarrhea in the developing world, [1] as well as the most common cause of travelers' diarrhea. [2] Insufficient data exists, but conservative estimates suggest that each year, about 157,000 deaths occur, mostly in children, from ETEC.
Referred to as E. coli O157:H7 or Shiga toxin-producing E. coli (STEC), this strain of E. coli can be particularly dangerous and even life-threatening. The primary sources of STEC outbreaks are ...
E. coli is a gram-negative, facultative anaerobe, nonsporulating coliform bacterium. [18] Cells are typically rod-shaped, and are about 2.0 μm long and 0.25–1.0 μm in diameter, with a cell volume of 0.6–0.7 μm 3. [19] [20] [21] E. coli stains gram-negative because its cell wall is composed of a thin peptidoglycan layer and an outer membrane.
Symptoms of E. coli infections usually start 3 to 4 days after swallowing the bacteria and most people recover without treatment after 5 to 7 days.
Doxycycline is added to most regimens in the treatment of pelvic infections to cover chlamydia and mycoplasma. Penicillin is effective for bacteremia caused by non-beta lactamase producing bacteria. However, other agents should be used for the therapy of bacteremia caused by beta-lactamase producing bacteria.
Within the penicillin class, pivmecillinam is considered the first-line empiric treatment for acute cystitis due to its wide spectrum of activity against gram-negative bacteria and its specific efficacy in the urinary tract. It has consistently demonstrated a high cure rate of over 85% for UTIs and a low resistance rate among E. coli strains.